FEROX STRATEGIES

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Illinois · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 3

Trade (domestic/foreign)

General issues related to trade.

Health Issues

General healthcare issues related to biosimilar industries.

Pharmacy

General patent issues related to biosimilar industries.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.